HomeMarketsSharesMerck & Co Inc - USD

Trade Merck & Co Inc - USD - MRK CFD

Market is not available at the momentMarket information is presented
as of 2026-10-16T20:45:46+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread1.6
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02224 %
(-$4.45)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


-0.02224%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00001 %
($0.00)

Trade size with leverage ~ $20,000.00

Money from leverage ~ $$19,000.00


0.00001%
Overnight funding adjustment time21:00 (UTC)
CurrencyUSD
Min traded quantity0.1
Margin5.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close144.71
Open144.8
1-Year Change71.97%
Day's Range144.37 - 147.31

Trade Merck & Co Inc - USD - MRK

Merck & Co., Inc. (MRK) is a healthcare company dealing in pharmaceuticals and animal health. Founded in 1891, Merck is headquartered in Kenilworth, New Jersey. 

The company provides pharmaceutical products around the world, offering an array of human healthcare solutions designed for areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular and diabetes. 

Apart from prescription medicines, Merck is known for its vaccine products for preventive diseases. A predecessor company to the present-day Merck made the first smallpox vaccine for commercial use in the United States in 1898 and was the maker of HPV vaccine Gardasil and painkiller Vioxx.

This biopharmaceutical company engages in research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. In 2021, Merck invested $12.2bn in research and development, especially to counter and help win the fight against coronavirus. It’s molnupiravir was given emergency use authorisation by the United States Food and Drug Administration (FDA) to counter mild-to-moderate Covid-19 in adults. 

Merck puts equal emphasis on animal health through Merck Animal Health, a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services.

The company engages and partners with several experts for early-stage science, clinical-stage programs, to deliver therapies and more. GlaxoSmithKline PLC (GSK), Johnson & Johnson (JJ) and many others are actively engaged with Merck.

Being more than a century old, Merck made it through two world wars and was a big part of the economic and business history of American public markets. Post-First World War, authorities seized the subsidiary of a German chemical maker to prevent the Kaiser from profiteering from American needs. Merck was re-established as an American corporation after the Second World War ended. 

The company went public on the New York Stock Exchange in 1946 under the symbol ‘MRK’.

Latest shares articles

BAE Systems stock forecast
BAE Systems stock forecast: H1 results, guidance upgrade
BAE Systems is a UK defence and aerospace group listed in London. In August 2026, it secured a $149.8m US Navy award for work on the USS Boxer. Explore third-party BA. price targets and technical analysis. Past performance is not a reliable indicator of future results.
07:18, 16 October 2026
TAURON stock forecast
TAURON stock forecast: H1 earnings
TAURON is a Polish energy group. In the first half of 2026, revenue was broadly flat, while EBITDA and net profit fell amid higher CO2 allowance costs and coal consumption. Explore third-party analyst targets and technicals. Past performance is not a reliable indicator of future results.
12:04, 12 October 2026
Puma stock forecast
Puma stock forecast: Anta stake deal cleared
Puma is a German sportswear company. Chinese regulators have cleared Anta Sports’ proposed acquisition of an approximately 29% stake, with completion expected before the end of 2026. Explore third-party PUM price targets. Past performance is not a reliable indicator of future results.
10:19, 12 October 2026
Dino Polska stock forecast
Dino Polska stock forecast: H1 sales growth slows
Dino Polska is a Polish grocery retailer. In H1 2026, revenue rose 12.5% year on year to 18.0bn PLN, while like-for-like sales growth slowed to 2.2%. Explore third-party DNP price targets and technical analysis. Past performance is not a reliable indicator of future results.
08:27, 12 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready